We have investigated the effects of the calcium-sensitizing inotropic agent EMD 57033 on Ca 2 + handling in intact and skinned rat ventricular myocytes. Intracellular Ca 2 + was monitored using fura 2. Myocytes were saponin-skinned, allowing study of sarcoplasmic reticulum (SR) function. In intact myocytes EMD 57033 (1-10 µmol/l) produced a concentration-dependent decrease in the amplitude of the Ca 2 + transient and prolonged its declining phase, but had no effect on the rise time. In skinned myocytes, the amplitude of spontaneous Ca 2 + release from the SR was decreased by EMD 57033 (5 and 10 µmol/l), although this agent had no significant effect on the frequency of spontaneous Ca 2 + release. In the presence of the cross-bridge inhibitor 2,3-butanedione monoxime (5 mmol/l), or in a low bathing Ca 2 + concentration (1 mmol/l), EMD 57033 (10 µmol/l) had smaller effects on both the amplitude and time course of the Ca 2 + transient in intact cells than in the absence of 2,3-butanedione monoxime or in the presence of 2 and 5 mmol/l Ca 2 + respectively. These data suggest that the effects of EMD 57033 on Ca 2 + are due to changes in Ca 2 + binding to troponin C, secondary to cross-bridge formation. Thus, during positive inotropy, EMD 57033 is unlikely to provoke arrhythmias due to effects on SR Ca 2 + handling. In intact cells, its effects on Ca 2 + handling would be expected to protect against arrhythmias.
A B S T R A C T
We have investigated the effects of the calcium-sensitizing inotropic agent EMD 57033 on Ca 2 + handling in intact and skinned rat ventricular myocytes. Intracellular Ca 2 + was monitored using fura 2. Myocytes were saponin-skinned, allowing study of sarcoplasmic reticulum (SR) function. In intact myocytes EMD 57033 (1-10 µmol/l) produced a concentration-dependent decrease in the amplitude of the Ca 2 + transient and prolonged its declining phase, but had no effect on the rise time. In skinned myocytes, the amplitude of spontaneous Ca 2 + release from the SR was decreased by EMD 57033 (5 and 10 µmol/l), although this agent had no significant effect on the frequency of spontaneous Ca 2 + release. In the presence of the cross-bridge inhibitor 2,3-butanedione monoxime (5 mmol/l), or in a low bathing Ca 2 + concentration (1 mmol/l), EMD 57033 (10 µmol/l) had smaller effects on both the amplitude and time course of the Ca 2 + transient in intact cells than in the absence of 2,3-butanedione monoxime or in the presence of 2 and 5 mmol/l Ca 2 + respectively. These data suggest that the effects of EMD 57033 on Ca 2 + are due to changes in Ca 2 + binding to troponin C, secondary to cross-bridge formation. Thus, during positive inotropy, EMD 57033 is unlikely to provoke arrhythmias due to effects on SR Ca
INTRODUCTION
The strength of contraction of the heart can be increased in two ways : first, by increasing the amount of Ca# + entering the cytoplasm to activate the contractile proteins ; and secondly, by increasing the response of the contractile proteins to cytoplasmic Ca# + . Until recently, most available inotropic agents worked by the first of these mechanisms [1] . Although effective, this approach has the disadvantage that an increased intracellular free Key words : arrhythmias, heart, inotropic agents, intracellular Ca# + , myofilaments, sarcoplasmic reticulum. Ca# + concentration ([Ca# + ] i ) can overload the sarcoplasmic reticulum (SR) with Ca# + . Under these conditions, the SR can spontaneously release sufficient Ca# + to activate inward currents, which may be arrhythmogenic [2] . More recently, therefore, agents have been developed which increase the strength of contraction by increasing the response of the contractile proteins to Ca# + [3] [4] [5] [6] [7] .
EMD 57033 is one such Ca# + -sensitizer, although its precise mechanism of action remains unclear. Previous studies have shown that the substantial increase in developed force produced by this agent (an approx. 130 % increase at 10 µM [5] ) is accompanied by a reduced amplitude of the Ca# + transient and by prolongation of the time course of contraction [5, 6] . Although both of these effects could, in theory, be explained by increased Ca# + binding to the regulatory protein troponin C, studies with isolated troponin C have shown that EMD 57033 has no effect on Ca# + binding to this protein [6] . It has been suggested, therefore, that EMD 57033 enhances Ca# + binding to the contractile proteins via the feedback that normally exists between formed cross-bridges and troponin C (increased cross-bridge formation leading to increased Ca# + binding to troponin C), either by enhancing cross-bridge formation or by enhancing the feedback from cross-bridge formation to Ca# + binding [7, 8] .
An increase in Ca# + binding (in effect, an increase in buffering for Ca# + ) would be expected to produce only a transient decrease in [Ca# + ] i [6] , since the steady-state level is determined by trans-sarcolemmal Ca# + flux. However, EMD 57033 apparently produces a sustained decrease in [Ca# + ] i , suggesting that it might have effects on cellular Ca# + cycling other than those mediated by increased myofilament Ca# + binding. Thus the purpose of the present study was to investigate the mechanism by which EMD 57033 alters Ca# + binding to the myofilaments and to determine whether EMD 57033 alters Ca# + cycling by the SR, which is quantitatively the most important source of Ca# + in cardiac muscle.
MATERIALS AND METHODS
All experiments were performed in accordance with the United Kingdom Home Office Guidance on the Operation of Animals (Scientific Procedures) Act 1986.
Ventricular myocyte isolation
Ventricular myocytes were isolated from adult female Wistar rat hearts, as described previously [9] . In brief, the animal was stunned, then killed by cervical dislocation. The heart was perfused retrogradely with a Hepes- 
Measurement of SR Ca 2 + release in skinned cells
Cells were skinned as described previously [10] . Isolated ventricular myocytes in Hepes\Tyrode solution were centrifuged (40 g, 45 s), the supernatant was removed, and the cells were resuspended in relaxing solution (see Solutions and chemicals section and Table 1) . This solution was then replaced by skinning solution, which was prepared by adding saponin (50 µg\ml ; BDH Laboratory Supplies, Poole, Dorset, U.K.) to the relaxing solution. After the myocytes had been permeabilized (chemically skinned) for 30 min with saponin, the skinning solution was replaced with relaxing solution and the skinned cells were stored at 4 mC.
For experiments, an aliquot of skinned cells was placed in the experimental bath (volume 80 µl) on the stage of an inverted microscope (Diaphot-TMD ; Nikon, Tokyo, Japan) and perfused at 8 µl\s with control solution (see Solutions and chemicals and Table 1 ) containing 150 nmol\l Ca# + and 10 µmol\l fura 2 (pentapotassium salt ; Molecular Probes Inc., Eugene, OR, U.S.A.). The single skinned cell under study was held on the bottom of the experimental bath using a glass pipette. Spontaneous Ca# + release from the SR of a single cell could be monitored by measuring the fura 2 fluorescence at 510 nm, collected by the objective lens (Nikon oil immersion Fluor i40 ; numerical aperture 1.30) and detected using a photomultiplier (Cairn Research Ltd, Faversham, Kent, U.K.), during alternate (every 2 ms) excitation by light of wavelengths 340 nm and 380 nm from a 100 W xenon lamp (Nikon). Shutters in the light 
Measuring Ca 2 + transients in intact cells
Ca# + transients were monitored in intact cells using almost the same methods and apparatus as for the skinned cells, except that the cells were loaded with fura 2 using the acetoxymethyl ester form of the dye (5 µmol\l for 13-15 min at room temperature ; Molecular Probes Inc.). Intact cells adhered to the glass bottom of the experimental chamber -it was not necessary to hold them down with a glass pipette. They were electrically stimulated at 0.33 Hz in Hepes\Tyrode solution (see Solutions and chemicals).
Solutions and chemicals
All solutions were prepared using ultra-pure water supplied by a Milli-Q system (Millipore Co., Bedford, MA, U.S.A.). For isolating the cells, three different solutions were used. The solutions for measuring Ca# + release in skinned cells (see Table 1 ) were as follows. (i) Relaxing solution was used for permeabilizing (skinning) the isolated cells and was Ca# + -free. (ii) Control solution induced spontaneous Ca# + release from the SR. The Ca# + concentration of this solution was adjusted by mixing relaxing solution plus 50 µmol\l Ca# + with Ca\EGTA solution. The free Ca# + concentration was calculated by solving simultaneous equations using the relevant binding constants [11,11a] .
The EMD 57033 was kept in DMSO as a 5-10 mmol\l stock solution ; the final concentration of DMSO in all experimental solutions was adjusted to 0.1 % (v\v). All chemicals were reagent grade. All experiments were carried out at room temperature (22-24 mC).
Calibration of Ca 2 + concentration
Calibration of the Ca# + concentration in the experimental solutions was carried out in the same apparatus using a range of solutions which contained 10 µmol\l fura 2, 10 mmol\l EGTA and various Ca# + concentrations (Table 1) . These solutions were prepared by mixing two complementary solutions in the same way as for the control solution for skinned cells (see Solutions and chemicals), i.e. an EGTA calibration solution was mixed with a Ca# + calibration solution (see Table 1 ). The apparent dissociation constant of EGTA for Ca# + was 267 nmol\l (at pH 7.1, 1 mmol\l Mg# + and 20 mC). Addition of 0.1 % DMSO or 5-10 µmol\l EMD 57033 to the calibrating solutions had no effect on the fura 2 fluorescence calibration curve in vitro : pCa 
Statistical analysis
Data are presented as meanspS.E.M., and statistical analysis was performed using paired t-tests or one-way ANOVA as appropriate. Statistical significance was taken as P 0.05, and is indicated as : *P 0.05, **P 0.01, ***P 0.001. of the Ca# + transient, which became more marked as the drug concentration was increased to 5 and then 10 µmol\l. This effect is shown graphically in Figure  1 (B), which shows mean data from six cells. EMD 57033 significantly decreased the amplitude of the Ca# + transient at all concentrations used, and the decrease in amplitude was greater at higher concentrations. Figure 1(C) shows that the decrease in the Ca# + transient amplitude was accompanied by prolongation of the declining phase. Figure 1(D) shows this effect quantitatively by plotting the time taken for the transient to decline by 75 % from its peak (DT75). DT75 was increased at all concentrations of EMD 57033, reaching statistical significance at the highest concentration used (10 µmol\l). In contrast, the rise time of the Ca# + transient, as quantified by the time taken for it to rise from the baseline to 75 % of peak amplitude (TP75), was unaffected by EMD 57033. shows spontaneous Ca# + release from the SR under control conditions. Increasing the concentration of EMD 57033 to 5 µmol\l ( Figure 2B ) and 10 µmol\l ( Figure 2C ) decreased the amplitude of the spontaneous Ca# + release. This is shown graphically in Figure 3 for 11 experiments, where both concentrations of EMD 57033 significantly decreased the amplitude of spontaneous Ca# + -induced release. EMD 57033 produced a small, though statistically insignificant, increase in the frequency of spontaneous Ca# + release ( Figure 3B) , and also slowed both the rising and declining phases of each spontaneous Ca# + release ( Figure 3C ). These data suggest that EMD 57033 may alter SR function. However, since at least some of these effects (e.g. the decreased amplitude of Ca# + release) could be due to increased Ca# + buffering within the cell and because EMD 57033 may increase functional Ca# + binding by the contractile proteins, one possibility is that the increased buffering comes from the myofilaments. We therefore tested this hypothesis in intact cells.
RESULTS

Effects of EMD
Effects of EMD 57033 on SR function in skinned ventricular myocytes
Effects of BDM and extracellular Ca 2 + concentration on the response of intact myocytes to EMD 57033
If EMD 57033 affects [Ca# + ] i via feedback from active cross-bridges to troponin C (see Introduction), then interventions which alter the number of force-generating cross-bridges would be expected to alter the response to EMD 57033. To test this idea, we investigated the effect of EMD 57033 in the presence of the cross-bridge inhibitor BDM, and also while promoting cross-bridge formation by raising the extracellular Ca# + concentration. Figure 4 shows the effects of BDM on the response to EMD 57033. In the absence of BDM, 10 µmol\l EMD 57033 caused a 29.5p4.4 % (n l 8) decrease in the amplitude of the Ca# + transient (Figures 4A and 4C) , with significant slowing of the declining phase ( Figures  4B and 4D) . Addition of 5 mmol\l BDM caused a small, but statistically significant, decrease in Ca# + -transient amplitude ( Figures 4A and 4C) , probably due to the known inhibitory effects of BDM on the SR [12] . This small decrease in Ca# + -transient amplitude was accompanied by a marked decrease in contraction (results not shown), mainly due to the inhibitory effects of BDM on the contractile proteins. Addition of 10 µmol\l EMD 57033 in the continued presence of BDM caused a 21.0p1.9 % (n l 8) decrease in Ca# + -transient amplitude ( Figures 4A and 4C ). This decrease was significantly smaller than that observed in the absence of BDM (P 0.05). EMD 57033 at 10 µmol\l also slowed the declining phase in the presence of BDM ( Figures 4B and  4D ), again to a smaller extent than in the absence of BDM (P 0.05). Figure 5 shows the effects of EMD 57033 on Ca# + -transient amplitude and time course when the extracellular Ca# + concentration was increased to 2 and 5 mmol\l. The Ca# + -transient amplitude increased to 118.6 % (not significant) and 145.2 % (P 0.01) of control in solutions containing 2 and 5 mmol\l Ca# + respectively ( Figure 5A ). The declining phase was slightly, but insignificantly, prolonged ( Figure 5B ). At each Ca# + concentration, EMD 57033 decreased the Ca# + -transient amplitude ( Figure 5A ) and prolonged the declining phase ( Figure 5B) . However, the drug-induced decrease in Ca# + -transient amplitude became more marked as the Ca# + concentration increased : to 82.1p3.7 % of control in 1 mmol\l Ca# + ; to 73.4p8.0 % of control in 2 mmol\l Ca# + ; and to 70.3p6.4 % of control in 5 mmol\l Ca# + . The prolongation of the declining phase caused by EMD 57033 also increased as the bathing Ca# + concentration was raised : to 136.6p10.1 % of control in 1 mmol\l Ca# + ; to 153.0p12.7 % in 2 mmol\l Ca# + ; and to 155.2p12.6 % of control in 5 mmol\l Ca# + ( Figure 5B ).
DISCUSSION
In the experiments described in the present paper, we have investigated the mechanism of action of the calciumsensitizing inotrope EMD 57033 by measuring [Ca# + ] i and SR Ca# + release in intact and skinned single cardiac myocytes. This approach has the advantage that it allows myofilament and SR function to be monitored in situ, while avoiding the problems associated with lack of homogeneity of cells, diffusion delays and (in skinned cells) unknown solution composition around the SR [10] .
Effects of EMD 57033 on the Ca 2 + transient
In the present study, EMD 57033 prolonged the declining phase of the Ca# + transient. However, in previous studies, the Ca# + transient was abbreviated, as predicted for a predominantly calcium-sensitizing effect [5, 8] . There are several possible reasons for this difference. The present study used isotonically shortening cells, whereas isometrically contracting papillary muscles were used previously. Isotonic contractions are abbreviated compared with isometric contractions (e.g. [13] ), and it has been suggested that this is due to shortening deactivation, i.e. cross-bridge detachment with a consequent decrease in Ca# + binding to troponin C [13] . This effect, i.e. decreasing feedback in the myofilaments, acts in the opposite direction to the suggested action of EMD 57033 (see Introduction and below), thus reducing the effect of the drug on the time course of the calcium transient. Differences between particular experimental preparations may also contribute. Abbreviation was seen in ferret cardiac muscle [5, 8] , but EMD 57033 had little effect on the Ca# + -transient time course in ventricular myocytes from guinea-pigs or Sprague-Dawley rats [3, 14] . This could be due both to the mechanism outlined above and to variations in other factors, such as phosphodiesterase activity, which varies in different species. Inhibition of phosphodiesterase -an effect also produced by EMD 57033 -causes myofilament desensitization, with predicted Ca# + -transient prolongation. Clearly, the overall effect on the Ca# + -transient time course depends on the balance of these factors in a given preparation.
EMD 57033 also decreased the Ca# + -transient amplitude, in agreement with previous studies. As discussed, one possibility is that this is due to increased Ca# + binding by troponin C, mediated by increased feedback from formed cross-bridges to troponin C. If so, Ca# + binding must increase sufficiently to decrease the amplitude regardless of the type of contraction, since this effect has been seen during both isometric [5, 8] and isotonic (the present study) contractions. This decrease in [Ca# + ] i would be expected to be anti-arrhythmogenic, by reducing the likelihood of arrhythmias due to Ca# + -activated currents. However, the dissociation between the effects on amplitude and time course indicates that, in at least some preparations, EMD 57033 has appreciable actions other than Ca# + -sensitization, and must either decrease efflux from or increase influx into the cytoplasmic compartment of the cell.
Effects of EMD 57033 on SR function
A possible explanation for the decreased Ca# + -transient amplitude in the presence of EMD 57033 is that EMD 57033 causes increased Ca# + buffering in the cell, possibly by increasing Ca# + binding to troponin C. This is discussed further in the next section. An alternative possibility, which is also raised by the decreased amplitude of spontaneous Ca# + release in skinned cells (see Introduction), is that the drug inhibits SR function. However, decreased SR Ca# + uptake would be expected to decrease the frequency of spontaneous Ca# + release [10] , whereas in fact a small increase was observed ; furthermore, the rising phase of the Ca# + transient, which is thought to reflect SR Ca# + release, was unaffected by EMD 57033 in intact cells (Figure 1) . Thus it appears most likely that EMD 57033 has no direct negative effect on SR function, and that the observed effects are due predominantly to an increase in Ca# + buffering within the cell.
Effects of EMD 57033 on contractile proteins
Previous data indicate that EMD 57033 increases Ca# + binding to the myofilaments, but has no effect on Ca# + binding to isolated troponin C [5, 6] . It has, therefore, been suggested that EMD 57033 acts via the feedback mechanism from the cross-bridges to troponin C [7, 8] , whereby an increase in cross-bridge formation leads to an increase in the Ca# + affinity of troponin C [13, 15, 16] . In the present experiments we used BDM to investigate this possibility, since BDM decreases active force by acting on the cross-bridges and decreases the feedback from the cross-bridges to troponin C [17] [18] [19] . The observation that the effects of EMD 57033 were reduced when cross-bridges were inhibited with BDM is thus consistent with the hypothesis that EMD 57033 acts by enhancing the feedback. This could occur if EMD 57033 facilitated the formation of more cross-bridges (e.g. by increasing the co-operativity of cross-bridge formation) or acted directly on the feedback process itself. Whatever the precise mechanism, increased feedback would increase Ca# + binding to troponin C and thus could cause increased cytoplasmic Ca# + buffering. Also consistent with this hypothesis, the effects of EMD 57033 were greater under conditions (raised bathing Ca# + concentration) in which more cross-bridges would be formed.
Positive inotropy and arrhythmias
In recent years the concept of positive inotropy as a treatment for heart failure has fallen from favour, largely because of the substantial risk of fatal arrhythmia that has been associated with it. However, all the major trials have used agents which raise [Ca# + ] i . Agents that act by increasing myofilament Ca# + sensitivity could potentially avoid this problem, in addition to possessing other theoretical advantages [7] . The data presented here suggest that the effects of the sensitizer EMD 57033 on [Ca# + ] i are due predominantly to increased cytoplasmic Ca# + buffering rather than to altered SR function, and are consistent with the hypothesis that the increased buffering is caused by enhanced Ca# + binding to troponin C due to enhanced feedback from cross-bridges to troponin C. The observed effects of EMD 57033 on [Ca# + ] i also suggest that this agent, or similar sensitizers, could simultaneously cause positive inotropy and inhibit arrhythmias caused by spontaneous Ca# + release from the SR.
